{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,12]],"date-time":"2026-09-12T11:53:16Z","timestamp":1789213996847,"version":"build-2803163510"},"reference-count":49,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2021,6,1]],"date-time":"2021-06-01T00:00:00Z","timestamp":1622505600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,6,1]],"date-time":"2021-06-01T00:00:00Z","timestamp":1622505600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2021,3,22]],"date-time":"2021-03-22T00:00:00Z","timestamp":1616371200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100004622","name":"Dutch Cancer Society","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004622","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Cancer Letters"],"published-print":{"date-parts":[[2021,6]]},"DOI":"10.1016\/j.canlet.2021.03.019","type":"journal-article","created":{"date-parts":[[2021,3,21]],"date-time":"2021-03-21T11:10:58Z","timestamp":1616325058000},"page":"18-29","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":10,"special_numbering":"C","title":["Pharmacological inhibition of 17\u03b2-hydroxysteroid dehydrogenase impairs human endometrial cancer growth in an orthotopic xenograft mouse model"],"prefix":"10.1016","volume":"508","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-4700-3404","authenticated-orcid":false,"given":"Sofia","family":"Xanthoulea","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gonda F.J.","family":"Konings","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Niina","family":"Saarinen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bert","family":"Delvoux","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8226-8665","authenticated-orcid":false,"given":"Loes F.S.","family":"Kooreman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pasi","family":"Koskimies","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Merja R.","family":"H\u00e4kkinen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Seppo","family":"Auriola","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elisabetta","family":"D'Avanzo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7342-6518","authenticated-orcid":false,"given":"Youssef","family":"Walid","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8470-386X","authenticated-orcid":false,"given":"Frank","family":"Verhaegen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9606-0889","authenticated-orcid":false,"given":"Natasja G.","family":"Lieuwes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Florian","family":"Caiment","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1305-9541","authenticated-orcid":false,"given":"Roy","family":"Kruitwagen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5900-6883","authenticated-orcid":false,"given":"Andrea","family":"Romano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"6","key":"10.1016\/j.canlet.2021.03.019_bib1","first-page":"394","article-title":"Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"68","author":"Bray","year":"2018","journal-title":"CA A Cancer J. Clin."},{"key":"10.1016\/j.canlet.2021.03.019_bib2","series-title":"Global Cancer Observatory: Cancer Tomorrow","author":"Ferlay","year":"2018"},{"issue":"20","key":"10.1016\/j.canlet.2021.03.019_bib3","doi-asserted-by":"crossref","first-page":"2607","DOI":"10.1200\/JCO.2012.48.2596","article-title":"Type I and II endometrial cancers: have they different risk factors?","volume":"31","author":"Setiawan","year":"2013","journal-title":"J. Clin. Oncol."},{"issue":"4","key":"10.1016\/j.canlet.2021.03.019_bib4","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1002\/cjp2.82","article-title":"Evaluation of endometrial carcinoma prognostic immunohistochemistry markers in the context of molecular classification","volume":"3","author":"Karnezis","year":"2017","journal-title":"J Pathol Clin Res"},{"issue":"10","key":"10.1016\/j.canlet.2021.03.019_bib5","doi-asserted-by":"crossref","first-page":"1584","DOI":"10.1111\/1471-0528.14490","article-title":"Biomarkers needed to predict progestin response in endometrial cancer","volume":"124","author":"Derbyshire","year":"2017","journal-title":"BJOG"},{"key":"10.1016\/j.canlet.2021.03.019_bib6","first-page":"429","article-title":"Past, present, and future of hormonal therapy in recurrent endometrial cancer","volume":"6","author":"Carlson","year":"2014","journal-title":"Int J Womens Health"},{"issue":"5","key":"10.1016\/j.canlet.2021.03.019_bib7","doi-asserted-by":"crossref","first-page":"785","DOI":"10.1038\/s41416-020-0925-4","article-title":"Oestrogen receptor pathway activity is associated with outcome in endometrial cancer","volume":"123","author":"van Weelden","year":"2020","journal-title":"Br. J. Canc."},{"issue":"9","key":"10.1016\/j.canlet.2021.03.019_bib8","doi-asserted-by":"crossref","DOI":"10.3390\/ijms19092547","article-title":"Development of an image-guided orthotopic xenograft mouse model of endometrial cancer with controllable estrogen exposure","volume":"19","author":"Konings","year":"2018","journal-title":"Int. J. Mol. Sci."},{"issue":"4","key":"10.1016\/j.canlet.2021.03.019_bib9","doi-asserted-by":"crossref","first-page":"E591","DOI":"10.1210\/jc.2011-2994","article-title":"Overexpression of 17beta-hydroxysteroid dehydrogenase type 1 increases the exposure of endometrial cancer to 17beta-estradiol","volume":"97","author":"Cornel","year":"2012","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"10.1016\/j.canlet.2021.03.019_bib10","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1016\/j.mce.2018.10.004","article-title":"Local estrogen metabolism (intracrinology) in endometrial cancer: a systematic review","volume":"489","author":"Cornel","year":"2019","journal-title":"Mol. Cell. Endocrinol."},{"issue":"2","key":"10.1016\/j.canlet.2021.03.019_bib11","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1002\/path.5004","article-title":"Blocking 17beta-hydroxysteroid dehydrogenase type 1 in endometrial cancer: a potential novel endocrine therapeutic approach","volume":"244","author":"Konings","year":"2018","journal-title":"J. Pathol."},{"issue":"1\u20132","key":"10.1016\/j.canlet.2021.03.019_bib12","doi-asserted-by":"crossref","first-page":"216","DOI":"10.1016\/j.mce.2008.10.022","article-title":"Estrone C15 derivatives--a new class of 17beta-hydroxysteroid dehydrogenase type 1 inhibitors","volume":"301","author":"Messinger","year":"2009","journal-title":"Mol. Cell. Endocrinol."},{"key":"10.1016\/j.canlet.2021.03.019_bib13","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1016\/j.jpba.2018.01.034","article-title":"Analysis by LC-MS\/MS of endogenous steroids from human serum, plasma, endometrium and endometriotic tissue","volume":"152","author":"Hakkinen","year":"2018","journal-title":"J. Pharmaceut. Biomed. Anal."},{"issue":"17","key":"10.1016\/j.canlet.2021.03.019_bib14","doi-asserted-by":"crossref","first-page":"i884","DOI":"10.1093\/bioinformatics\/bty560","article-title":"fastp: an ultra-fast all-in-one FASTQ preprocessor","volume":"34","author":"Chen","year":"2018","journal-title":"Bioinformatics"},{"issue":"1","key":"10.1016\/j.canlet.2021.03.019_bib15","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1093\/bioinformatics\/bts635","article-title":"STAR: ultrafast universal RNA-seq aligner","volume":"29","author":"Dobin","year":"2013","journal-title":"Bioinformatics"},{"key":"10.1016\/j.canlet.2021.03.019_bib16","doi-asserted-by":"crossref","DOI":"10.1186\/1471-2105-12-323","article-title":"RSEM: accurate transcript quantification from RNA-Seq data with or without a reference genome","volume":"12","author":"Li","year":"2011","journal-title":"BMC Bioinf."},{"issue":"12","key":"10.1016\/j.canlet.2021.03.019_bib17","doi-asserted-by":"crossref","first-page":"550","DOI":"10.1186\/s13059-014-0550-8","article-title":"Moderated estimation of fold change and dispersion for RNA-seq data with DESeq2","volume":"15","author":"Love","year":"2014","journal-title":"Genome Biol."},{"issue":"Database issue","key":"10.1016\/j.canlet.2021.03.019_bib18","doi-asserted-by":"crossref","first-page":"D793","DOI":"10.1093\/nar\/gks1055","article-title":"The ConsensusPathDB interaction database: 2013 update","volume":"41","author":"Kamburov","year":"2013","journal-title":"Nucleic Acids Res."},{"issue":"1\u20132","key":"10.1016\/j.canlet.2021.03.019_bib19","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1016\/j.mce.2005.11.042","article-title":"Evaluation of inhibitors for 17beta-hydroxysteroid dehydrogenase type 1 in vivo in immunodeficient mice inoculated with MCF-7 cells stably expressing the recombinant human enzyme","volume":"248","author":"Husen","year":"2006","journal-title":"Mol. Cell. Endocrinol."},{"issue":"11","key":"10.1016\/j.canlet.2021.03.019_bib20","doi-asserted-by":"crossref","first-page":"5333","DOI":"10.1210\/en.2006-0778","article-title":"Human hydroxysteroid (17-beta) dehydrogenase 1 expression enhances estrogen sensitivity of MCF-7 breast cancer cell xenografts","volume":"147","author":"Husen","year":"2006","journal-title":"Endocrinology"},{"issue":"49","key":"10.1016\/j.canlet.2021.03.019_bib21","doi-asserted-by":"crossref","first-page":"81645","DOI":"10.18632\/oncotarget.13162","article-title":"Sprouty2 inhibits amphiregulin-induced down-regulation of E-cadherin and cell invasion in human ovarian cancer cells","volume":"7","author":"Cheng","year":"2016","journal-title":"Oncotarget"},{"issue":"8","key":"10.1016\/j.canlet.2021.03.019_bib22","doi-asserted-by":"crossref","DOI":"10.3390\/cells8080808","article-title":"Two members of a family known to inhibit FGF-mediated signaling, exert opposing roles on proliferation and migration of glioblastoma-derived cells","volume":"8","author":"Celik-Selvi","year":"2019","journal-title":"Cells"},{"issue":"10","key":"10.1016\/j.canlet.2021.03.019_bib23","doi-asserted-by":"crossref","first-page":"2092","DOI":"10.1111\/jcmm.12368","article-title":"KITLG is a novel target of miR-34c that is associated with the inhibition of growth and invasion in colorectal cancer cells","volume":"18","author":"Yang","year":"2014","journal-title":"J. Cell Mol. Med."},{"issue":"4","key":"10.1016\/j.canlet.2021.03.019_bib24","doi-asserted-by":"crossref","first-page":"1687","DOI":"10.1093\/nar\/gkw1093","article-title":"Histone demethylase PHF8 promotes epithelial to mesenchymal transition and breast tumorigenesis","volume":"45","author":"Shao","year":"2017","journal-title":"Nucleic Acids Res."},{"issue":"10","key":"10.1016\/j.canlet.2021.03.019_bib25","doi-asserted-by":"crossref","first-page":"2330","DOI":"10.1002\/ijc.28557","article-title":"Identification of genes expressed by immune cells of the colon that are regulated by colorectal cancer-associated variants","volume":"134","author":"Peltekova","year":"2014","journal-title":"Int. J. Canc."},{"issue":"3","key":"10.1016\/j.canlet.2021.03.019_bib26","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1517\/14728222.2012.741122","article-title":"The potential of carboxypeptidase M as a therapeutic target in cancer","volume":"17","author":"Denis","year":"2013","journal-title":"Expert Opin. Ther. Targets"},{"issue":"6","key":"10.1016\/j.canlet.2021.03.019_bib27","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1016\/j.neo.2019.03.011","article-title":"Epigenetically down-regulated acetyltransferase PCAF increases the resistance of colorectal cancer to 5-fluorouracil","volume":"21","author":"Liu","year":"2019","journal-title":"Neoplasia"},{"issue":"1","key":"10.1016\/j.canlet.2021.03.019_bib28","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1186\/s12964-019-0412-9","article-title":"Estrogen inhibits autophagy and promotes growth of endometrial cancer by promoting glutamine metabolism","volume":"17","author":"Zhou","year":"2019","journal-title":"Cell Commun. Signal."},{"issue":"1","key":"10.1016\/j.canlet.2021.03.019_bib29","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1158\/0008-5472.CAN-08-1648","article-title":"TGFBI deficiency predisposes mice to spontaneous tumor development","volume":"69","author":"Zhang","year":"2009","journal-title":"Canc. Res."},{"issue":"1","key":"10.1016\/j.canlet.2021.03.019_bib30","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1038\/onc.2011.213","article-title":"The tumor-suppressor gene ARHI (DIRAS3) suppresses ovarian cancer cell migration through inhibition of the Stat3 and FAK\/Rho signaling pathways","volume":"31","author":"Badgwell","year":"2012","journal-title":"Oncogene"},{"issue":"3","key":"10.1016\/j.canlet.2021.03.019_bib31","doi-asserted-by":"crossref","first-page":"307","DOI":"10.2478\/raon-2019-0034","article-title":"Dusp6 inhibits epithelial-mesenchymal transition in endometrial adenocarcinoma via ERK signaling pathway","volume":"53","author":"Fan","year":"2019","journal-title":"Radiol. Oncol."},{"issue":"4","key":"10.1016\/j.canlet.2021.03.019_bib32","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1016\/j.contraception.2018.05.020","article-title":"Molecular characterization of PRM-associated endometrial changes, PAEC, following mifepristone treatment","volume":"98","author":"Berger","year":"2018","journal-title":"Contraception"},{"issue":"16","key":"10.1016\/j.canlet.2021.03.019_bib33","first-page":"4870","article-title":"Identification of the mutational landscape of gynecological malignancies","volume":"11","author":"Chava","year":"2020","journal-title":"J. Canc."},{"issue":"5","key":"10.1016\/j.canlet.2021.03.019_bib34","doi-asserted-by":"crossref","first-page":"851","DOI":"10.1530\/ERC-15-0319","article-title":"Comprehensive genetic assessment of the ESR1 locus identifies a risk region for endometrial cancer","volume":"22","author":"O'Mara","year":"2015","journal-title":"Endocr. Relat. Canc."},{"issue":"45","key":"10.1016\/j.canlet.2021.03.019_bib35","doi-asserted-by":"crossref","first-page":"4778","DOI":"10.1038\/onc.2011.632","article-title":"ETV5 cooperates with LPP as a sensor of extracellular signals and promotes EMT in endometrial carcinomas","volume":"31","author":"Colas","year":"2012","journal-title":"Oncogene"},{"issue":"6","key":"10.1016\/j.canlet.2021.03.019_bib36","doi-asserted-by":"crossref","first-page":"1234","DOI":"10.1158\/0008-5472.CAN-19-1382","article-title":"ETV4 is necessary for estrogen signaling and growth in endometrial cancer cells","volume":"80","author":"Rodriguez","year":"2020","journal-title":"Canc. Res."},{"key":"10.1016\/j.canlet.2021.03.019_bib37","doi-asserted-by":"crossref","first-page":"940","DOI":"10.3389\/fphar.2018.00940","article-title":"Intracrine regulation of estrogen and other sex steroid levels in endometrium and non-gynecological tissues; Pathology, physiology, and drug discovery","volume":"9","author":"Konings","year":"2018","journal-title":"Front. Pharmacol."},{"key":"10.1016\/j.canlet.2021.03.019_bib38","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1016\/j.mce.2018.08.004","article-title":"Role of hydroxysteroid (17beta) dehydrogenase type 1 in reproductive tissues and hormone-dependent diseases","volume":"489","author":"Heinosalo","year":"2019","journal-title":"Mol. Cell. Endocrinol."},{"issue":"3","key":"10.1016\/j.canlet.2021.03.019_bib39","doi-asserted-by":"crossref","first-page":"1443","DOI":"10.2353\/ajpath.2010.090325","article-title":"Novel hydroxysteroid (17beta) dehydrogenase 1 inhibitors reverse estrogen-induced endometrial hyperplasia in transgenic mice","volume":"176","author":"Saloniemi","year":"2010","journal-title":"Am. J. Pathol."},{"issue":"1","key":"10.1016\/j.canlet.2021.03.019_bib40","doi-asserted-by":"crossref","first-page":"276","DOI":"10.1210\/jc.2013-2851","article-title":"Inhibition of type 1 17beta-hydroxysteroid dehydrogenase impairs the synthesis of 17beta-estradiol in endometriosis lesions","volume":"99","author":"Delvoux","year":"2014","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"10.1016\/j.canlet.2021.03.019_bib41","doi-asserted-by":"crossref","first-page":"757","DOI":"10.2147\/DDDT.S180836","article-title":"siRNA-based breast cancer therapy by suppressing 17beta-hydroxysteroid dehydrogenase type 1 in an optimized xenograft cell and molecular biology model in vivo","volume":"13","author":"Li","year":"2019","journal-title":"Drug Des. Dev. Ther."},{"issue":"1","key":"10.1016\/j.canlet.2021.03.019_bib42","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1016\/j.ygyno.2018.12.018","article-title":"Endocrine therapy in endometrial cancer: an old dog with new tricks","volume":"153","author":"Jerzak","year":"2019","journal-title":"Gynecol. Oncol."},{"key":"10.1016\/j.canlet.2021.03.019_bib43","doi-asserted-by":"crossref","first-page":"359","DOI":"10.3389\/fonc.2019.00359","article-title":"Anti-estrogen treatment in endometrial cancer: a systematic review","volume":"9","author":"van Weelden","year":"2019","journal-title":"Front Oncol"},{"key":"10.1016\/j.canlet.2021.03.019_bib44","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1186\/1471-2407-14-68","article-title":"Examestane in advanced or recurrent endometrial carcinoma: a prospective phase II study by the Nordic Society of Gynecologic Oncology (NSGO)","volume":"14","author":"Lindemann","year":"2014","journal-title":"BMC Canc."},{"issue":"20","key":"10.1016\/j.canlet.2021.03.019_bib45","doi-asserted-by":"crossref","first-page":"2607","DOI":"10.1200\/JCO.2012.48.2596","article-title":"Type I and II endometrial cancers: have they different risk factors?","volume":"31","author":"Setiawan","year":"2013","journal-title":"J. Clin. Oncol."},{"issue":"5","key":"10.1016\/j.canlet.2021.03.019_bib46","doi-asserted-by":"crossref","first-page":"1180","DOI":"10.1093\/annonc\/mdy058","article-title":"Final validation of the ProMisE molecular classifier for endometrial carcinoma in a large population-based case series","volume":"29","author":"Kommoss","year":"2018","journal-title":"Ann. Oncol."},{"issue":"6","key":"10.1016\/j.canlet.2021.03.019_bib47","doi-asserted-by":"crossref","DOI":"10.3390\/ijms21062227","article-title":"Aromatase inhibitors as adjuvant treatment for ER\/PgR positive stage I endometrial carcinoma: a retrospective cohort study","volume":"21","author":"Paleari","year":"2020","journal-title":"Int. J. Mol. Sci."},{"issue":"1","key":"10.1016\/j.canlet.2021.03.019_bib48","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1016\/j.ygyno.2019.05.007","article-title":"Phase 2 study of anastrozole in recurrent estrogen (ER)\/progesterone (PR) positive endometrial cancer: the PARAGON trial - ANZGOG 0903","volume":"154","author":"Mileshkin","year":"2019","journal-title":"Gynecol. Oncol."},{"issue":"8","key":"10.1016\/j.canlet.2021.03.019_bib49","doi-asserted-by":"crossref","first-page":"930","DOI":"10.1200\/JCO.2014.58.3401","article-title":"Phase II study of everolimus and letrozole in patients with recurrent endometrial carcinoma","volume":"33","author":"Slomovitz","year":"2015","journal-title":"J. Clin. Oncol."}],"container-title":["Cancer Letters"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0304383521001245?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0304383521001245?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,4]],"date-time":"2025-10-04T15:56:03Z","timestamp":1759593363000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0304383521001245"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,6]]},"references-count":49,"alternative-id":["S0304383521001245"],"URL":"https:\/\/doi.org\/10.1016\/j.canlet.2021.03.019","relation":{},"ISSN":["0304-3835"],"issn-type":[{"value":"0304-3835","type":"print"}],"subject":[],"published":{"date-parts":[[2021,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Pharmacological inhibition of 17\u03b2-hydroxysteroid dehydrogenase impairs human endometrial cancer growth in an orthotopic xenograft mouse model","name":"articletitle","label":"Article Title"},{"value":"Cancer Letters","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.canlet.2021.03.019","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 The Authors. Published by Elsevier B.V.","name":"copyright","label":"Copyright"}]}}